ABT 606 VS ACYCLOVIR FOR TREATMENT OF HERPES ZOSTER

待检验的假设是ABT-606在治疗VZV感染中具有潜在的应用。 这是一项阳性对照、双盲、双模拟、随机、四组、平行、多中心临床试验，在50岁及以上活动性无并发症带状疱疹感染患者中进行。 患者必须在带状疱疹样皮疹/水疱出现后72小时内入组。 研究分为两个阶段：急性评估期（第1-28天）和随访期（第29天-研究结束）。 大约400例符合入选标准的患者将以平衡的方式随机分配，每个治疗组随机分配100例患者，预计每家研究中心将入组2-10例患者。 研究的总持续时间为六个月。 本研究的意义在于，ABT-606可能是治疗带状疱疹的有效和安全的替代阿昔洛韦。

The hypothesis to be tested is that ABT-606 has potential application in the treatment of VZV infections. This is a positive control, double-blind, double-dummy, randomized, four-arm, parallel, multicenter clinical trial in patients 50 years and older with active uncomplicated herpes zoster infection. To be eligible patients must enroll within 72 hours of the appearance of zosteriform rash/vesicles. The study is divided into two periods; the Acute Assessment Period (days 1-28) and the Follow-up Perod (days 29-end of study). Approximately 400 patients who satisfy the entry criteria will be randomized in a balanced fashion so that 100 patients are randomized to each treatment arm. It is expected that each site will enroll 2-10 patients. The total duration of the study is six months. The significance of this study is that ABT-606 may be an effective and safe alternative to acyclovir for the treatment of shingles.